Vera Therapeutics (VERA)
$
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
About
Business overview of Vera Therapeutics (VERA)
Vera Therapeutics Inc is a clinical stage biotechnology company. It is focused on developing and commercializing transformative treatments for patients with serious immunological diseases. The company's product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection once weekly that blocks both B lymphocyte stimulator and a proliferation-inducing ligand, which stimulate B cells and plasma cells to produce autoantibodies contributing to certain autoimmune diseases.
Key Insights
Critical company metrics and information
Share Price
$47.51Market Cap
$3.01 BillionTotal Outstanding Shares
63.32 Million SharesTotal Employees
82Dividend
No dividendIPO Date
May 14, 2021SIC Description
Pharmaceutical PreparationsHomepage
https://www.veratx.com
Historical Stock Splits
Execution Date | Split Amount |
---|---|
No Historical Stock Splits |
Cash Flow Statement
October 1, 2023 to September 30, 2024
Metric | Value |
---|---|
Net Cash Flow From Operating Activities | $-120.64 Million |
Net Cash Flow From Investing Activities | $-185.09 Million |
Net Cash Flow From Financing Activities | $305.55 Million |
Net Cash Flow From Financing Activities, Continuing | $305.55 Million |
Net Cash Flow, Continuing | $-185,000.00 |
Net Cash Flow From Operating Activities, Continuing | $-120.64 Million |
Net Cash Flow From Investing Activities, Continuing | $-185.09 Million |
Net Cash Flow | $-185,000.00 |
Income Statement
October 1, 2023 to September 30, 2024
Metric | Value |
---|---|
Research and Development | $113.61 Million |
Income/Loss From Continuing Operations Before Tax | $-134.38 Million |
Operating Income/Loss | $-145.28 Million |
Net Income/Loss Attributable To Noncontrolling Interest | $0.00 |
Operating Expenses | $145.28 Million |
Basic Average Shares | $54.12 Million |
Other Operating Expenses | $31.67 Million |
Diluted Earnings Per Share | $-2.61 |
Net Income/Loss Attributable To Parent | $-134.38 Million |
Nonoperating Income/Loss | $10.91 Million |
Basic Earnings Per Share | $-2.61 |
Income/Loss From Continuing Operations After Tax | $-134.38 Million |
Diluted Average Shares | $54.12 Million |
Revenues | $0.00 |
Net Income/Loss | $-134.38 Million |
Preferred Stock Dividends And Other Adjustments | $0.00 |
Net Income/Loss Available To Common Stockholders, Basic | $-134.38 Million |
Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $0.00 |
Balance Sheet
October 1, 2023 to September 30, 2024
Metric | Value |
---|---|
Current Assets | $364.13 Million |
Fixed Assets | $368,000.00 |
Equity | $289.06 Million |
Current Liabilities | $26.46 Million |
Liabilities | $79.50 Million |
Assets | $368.56 Million |
Noncurrent Liabilities | $53.04 Million |
Other Non-current Assets | $4.06 Million |
Long-term Debt | $50.47 Million |
Other Current Liabilities | $18.22 Million |
Noncurrent Assets | $4.43 Million |
Liabilities And Equity | $368.56 Million |
Other Non-current Liabilities | $2.57 Million |
Accounts Payable | $4.60 Million |
Equity Attributable To Noncontrolling Interest | $0.00 |
Wages | $3.64 Million |
Equity Attributable To Parent | $289.06 Million |
Historical Dividends
Announcement Date | Payment Date | Record Date | Amount | Frequency |
---|---|---|---|---|
No historical dividends |
Boost your savings and earn 4.35% APY with a Marcus by Goldman Sachs savings account, a rate that's 8x the national averagewhen signing up with Financhle. No fees, no minimum deposits, backed by the financial expertise of Goldman Sachs. Terms apply.
â“’ 2024 Financhle. All Rights Reserved.